Stability indicating analytical method development and validation of some drugs in pharmaceutical dosage form

Abstract

quotBackground: Currently, the biggest challenge facing the pharmaceutical industry is estimating new medications in combined bulk and dose forms without any interreference of impurities. To prevent hypertension and anti-diabetic medications are often prescribed for typical lifestyle problems that are seen all over the world. In accordance with ICH Q2 (R2) Guidelines, the current work describes a straightforward, specific, exact, accurate, and robust. newlineAim: A fast, easy, robust, accurate, and economical way to measure several anti-diabetic and anti-hypertensive drugs with RP-HPLC method in dosage form. newlineMaterial and Methods: Separation was accomplished for empagliflozin and linagliptin impurities on ACE 3C18 PFP (250 mm x 4.6mm), 3µm. The mobile phase A used in the gradient liquid chromatographic technique has an ACN: buffer ratio of 88:12 (v/v). The mobile phase B used was an organic blend of ACN and MeOH that was 90:10 (v/v). To make the buffer, 1 mL of orthophosphoric acid was diluted with 1000 ml filtered water. newlineFor olmesartan medoxomil genotoxic impurities separated on Kromasil 100-5 C18 (250 x 4.6 mm x 5 m) column. Additionally, a ghost-busting column. Orthophosphoric acid, in the mobile phase A, was 0.1%. Methanol and acetonitrile were combined in the mobile phase B at a volume ratio of 75:925. newlineTo separate the paroxetine mesylate compound and paroxetine nitrosamine compound, a Luna Phenyl hexyl 100 A° column of (150 x 4.6) mm, 3 µm was employed. Formic acid was present in mobile phase A at a quantity of 0.1%. Mobile phase B made use of methanol. newlineThis separation was achieved using a Kromasil C18 column (250 X 4.6) mm 5and#956;m for the chromatographic separation. Additionally, a ghost-busting column was deployed. Acetonitrile was used in mobile phase B, while 0.1% orthophosphoric acid was used in mobile phase A. newlineResults and Discussion: Two unknown degradation impurity of linagliptin was identified. simultaneous estimation of genotoxic impurities in olmesartan medoxomil had been carried out by the developing RP-HPLC